SlideShare a Scribd company logo
1 of 28
Download to read offline
July 2014
Safe Harbor Statement
2
Statements made in this presentation regarding VeriTeQ Corporation (“VeriTeQ” or “Company”) and VeriTeQ that
are not historical facts are forward-looking statements based on our current expectations, assumptions, estimates
and projections about VeriTeQ and our industry. These forward-looking statements are subject to risks and
uncertainties that could cause actual future events or results to differ materially from such statements. These
forward-looking statements include, without limitation, statements about our proposed name change and reverse
stock split, our commercialization activities, market opportunities, our strategy, our competition, FDA regulation,
partnership opportunities, market penetration, and all other forward-looking statements. You should not place
undue reliance on any of the forward-looking statements made in this presentation. Our actual results could differ
materially from those expressed or implied by these forward-looking statements as a result of various factors,
including risks and uncertainties related to the timing or successful completion of our product commercialization
activities, VeriTeQ’s ability to raise capital, and other various risks and uncertainties. Additional information about
these and other factors that could affect VeriTeQ’s business is set forth in its various filings with the Securities and
Exchange Commission, including those set forth in its Form 10-K filed on April 15, 2014, and Forms 10-Q filed
on July 16, 2013 and November 14, 2013, and May 14, 2014 under the caption "Risk Factors." The Company
undertakes no obligation to update publicly any forward-looking statements for any reason, even if new
information becomes available or other events occur in the future.
This presentation does not constitute a prospectus or form part of any offer or invitation to sell or issue, or any
solicitation of any offer to purchase or subscribe for, or any offer to underwrite or otherwise acquire any shares in
the Company or any other securities, nor shall they or any part of them nor the fact of their distribution or
communication form the basis of, or be relied on in connection with, any contract, commitment or investment
decision in relation thereto, nor does it constitute a recommendation regarding the securities of the Company.
Company Background
3
VeriTeQ originated as a private company founded
in 2011 to acquire and develop core implantable
RFID intellectual property for healthcare
Acquired/licensed/developed 100+ patents (issued or
pending)
Multiple regulatory clearances: FDA and CE Mark
Completed share exchange agreement with
DigitalAngel Corporation on July 8, 2013;
company changed its name toVeriTeQ
VeriTeQ shareholders own ~88% of resulting company
Closed $1.5m bridge financing on Nov. 13
Ticker changed to “VTEQ” on Nov. 19
Unique Value Proposition
4
In July 2012, the Healthcare Safety and Innovation Act was signed into law and in Sept.
2013, the FDA issued a Final Rule requiring all medical devices in the U.S. that are re-
usable and re-processed to carry a unique device identifier, or UDI, with direct part
marking
VeriTeQ’s FDA cleared UDI, called Q Inside SafetyTechnology, can serve as a direct
part marking to help device manufacturers comply with the Final Rule, and can also
identify a permanent implantable medical device, in vivo, on demand
Q Inside SafetyTechnology goes beyond device identification and provides clinical and healthcare
benefits via customizable software and data analytics
VeriTeQ also offers FDA cleared radiation dose measurement technologies to protect
patients undergoing cancer treatment
VeriTeQ’s implantable and wearable dosimetry products provide radiation levels from the patient
to help prevent overdose and under-dose
Company Overview
5
VeriTeQ provides proprietary, innovative healthcare solutions for
Unique Device Identification and Bio-Sensing/Radiation Dosimetry
applications
CoreTechnology: implantable radio frequency (RF) microchip technology
Cleared by the FDA as the Predicate Class II medical device in the industry
UDI products enable access to UDI information, in-situ, on demand, at
the point of use
A leading industry position to enable compliance with FDA Final Rule
Q Inside SafetyTechnology also enables data analytics for evidence-based
medicine
Bio-sensing technologies for radiation dosimetry provide real-time
measurements of received radiation dose from the patient, not the
machine
External and internal product applications
Helps prevent radiation overdosing and under-dosing
Lead Business Areas
6
Medical Device
UDI/Q Inside
SafetyTechnology
Breast Implants
and Breast
Implant Sizers
Vascular Ports
Other Reusable
and Implantable
Medical Devices
Bio-
Sensing/Radiation
Dosimeter
Technologies
External
Radiation
Dosimeter
Implantable
Radiation
Dosimeter
TheVeriTeQ UDI System
Medical Devices with
Inside
SafetyTechnology
7
FDA Final Rule
8
The Final Rule requires devices intended to be used more than once and intended to undergo any
form of reprocessing before each use, i.e. re-useable/reprocessed medical devices to have a direct
part marking (vs. basic labeling on device packaging)
Requires the direct part marking to be provided through either or both of the following:
Easily readable plain text;
Automatic Identification and Data Capture (AIDC), or an alternative technology, that will provide the UDI
of the device on demand
Benefits of a UDI System
Allows more accurate reporting and analysis of adverse events to quickly identify problem devices
Reduces medical errors by quickly and accurately identifying a device and its characteristics
Provides a standardized identifier that allows manufacturers, distributors and healthcare facilities
to more effectively manage medical device recalls
Provides a consistent way to enter information about devices in electronic health records and
clinical information systems
Provides a foundation for a global, secure distribution chain, helping to address counterfeiting and
diversion and prepare for medical emergencies
 Implantable RFID
Microchips
 Patented and FDA
cleared
 Provides the primary
key information
 Pocket Readers
 Patented and FDA
Cleared
 Pocket Reader
 Pocket Reader EX
VeriTeQ’s UDI System: Inside
 Database
 Customization
for device
manufacturer
 Informatics
 Integration with
FDA database
9
UDI Business Model
10
VeriTeQ acts primarily as a supplier of its proprietary microchips and readers to
medical device manufacturers
Manufacturers incorporateVeriTeQ’s products into their manufacturing
processes/distribution strategy (to hospitals, physicians, etc.)
Price per chip = $12-15; gross margin per chip = 65 - 75% margins
Price per reader = $300-500; gross margin per reader = 40 – 60% margins
VeriTeQ also provides development services to medical device manufacturers
Primary development areas include design and manufacturing process to include chip
in their medical device, i.e. new encasement technologies such as special polymers
and heat resistant microchips
Avg. price for development per manufacturer = $250,000; gross margin = 50%
Data services include database connectivity to manufactured microchips,
application software to collect microchip/medical device model implanted,
FDA data base registry and informatics analytics. Priced on per project
development ranging from $25,000 to several hundred thousand dollars
Targeted Customers
11
Breast
Implant/Sizers
Manufacturers
Vascular Port
Manufacturers
Artificial
Joint/Sizers
Manufacturers
HeartValue Sizers,
Endo/ Surgical
Equipment
Breast Implants
12
VeriTeQ’s Q Inside SafetyTechnology can be embedded within breast
implants and sizers to automatically identify the medical device in situ
or after re-sterilization.
Ex-US:Agreement with Establishment Labs/Motiva
Leading global breast, body and facial aesthetic company that manufactures
advanced silicone-filled breast implants, marketed under the Motiva
Implant Matrix brand name
Manufacturing completed and CE Mark certifications achieved
Launched Q1-2014 (EU and UK); Over 500 women implanted
US: Market leading breast implant manufacturer is testing feasibility to
integrate the Q Inside in its silicone implants and sizers
Discussions ongoing with the two leading global breast implant
manufacturers regarding need to identify their sizers to comply with
FDA Final Rule
Company estimates sizer market at 600,000 devices annually
Vascular Ports
13
Partnership with Medcomp (a leading manufacturer of
vascular ports) to utilize Q Inside for Medcomp’s FDA-cleared
vascular ports
$3 million initial contractual PO commitment from Medcomp
Enables accurate device identification and medication dosage
Hospital studies expected to begin at:
Northwestern Memorial in Chicago
NewYork-Presbyterian – University Hospital of Columbia and Cornell
in NY
Cleveland Clinic in Cleveland, OH or MDAnderson Cancer Center in
Houston,TX
Medcomp /VeriTeQ targeting to set clinical UDI standard to
incentivize other port manufacturers to use Q Inside – e.g.
C.R. Bard, Smiths Medical, etc.
Artificial Joints and Sizers
14
Identification of implantable and reusable medical devices such as
sizers used in joint replacements (subject to Final Rule)
Artificial hips in the U.S.:
Number of procedures: 230,000
Total annual expenditure: $10.5 billion
Average cost per procedure: $45,000
Major manufacturers: Zimmer (24%), Stryker, DePuy/J&J, Biomet,Wright
Medical
Artificial knees in the U.S.
Number of procedures: 543,000
Total annual expenditure: $12 billion
Average cost per procedure: $22,000
Major manufacturers: Zimmer (24%), Depuy/J&J, Stryker, Biomet, Smith &
Nephew
Active initial meetings/dialog with lead target device
manufacturers
Clinical benefits: Q Inside SafetyTechnology allows for immediate data
retrieval; can help quickly resolve adverse event reporting and recalls
As published on July 18,2011 in 24/7Wall St.’s Eleven Most Implanted Medical Devices In America
VeriTeQ Bio-Sensors
In Situ Measurement of
Radiation Dosages
15
Sensing Technologies
16
VeriTeQ owns Patent 7,125,382 for an “Embedded Bio-Sensor
System,” a biological sensor on the end of a radio frequency chip
Temperature (current)
Radiation levels (current)
Blood oxygen (future)
Pulse (future)
Medication levels (future)
i.e. post surgery
Glucose (licensed to a third party)
Others
VeriTeQ Dosimetry
OneDose
ExternalTechnology
Q Inside SmartMarker
ImplantableTechnology
Radiation DoseVerification
17
Maximize
Tumor Control
(High Dose)
Minimize
Healthy Tissue
Toxicity
(Low Dose)
The greatest challenge for radiation therapy or any cancer therapy is to attain the
highest probability of cure with the least morbidity.1
1) Bucci MK, Bevan A and Roach M. Ca Cancer J Clin 2005;55:117-134
Objective of the Radiation Oncologist
18
Patient Safety & Radiation Overdose
19
2013: #3 Unnecessary exposures and
radiation burns from diagnostic
radiology procedures
2012: #2 Exposure hazards from
radiation therapy and CT
2011: #1 Radiation overdose and
other errors during radiation therapy
2009-10: #4 CT radiation dose
2008: #8 CT radiation dose
2007: #5 Radiation therapy errors
According to the ECRI Institute, radiation or CT overdose make the list of theTop
10Technology Hazards each year going back at least five years
VeriTeQ OneDose ®
20
OneDose® is an FDA-cleared single-use, external dosimetry system used in
the radiation oncology suite to verify radiation dose quickly and conveniently
at the skin level
Significant IP protection
CE Mark to market products in the E.U.
OneDose is the only wireless, pre-calibrated, disposable, surface sensor on
the market that provides an instant readout of the dose delivered
Reimbursement rate per patient (4-6 dosimeters used during treatment)
ranges between $260 and $380
In 2010, 1.1 million patients received radiation therapy in the U.S.* with
new indications for use in CT and fluoroscopy markets
Researchers at the National Cancer Institute estimate that 29,000 future cancer cases could
be attributed to the 72 million CT scans performed in the country in 2007
Over 5 million fluoroscopic procedures performed annually in the U.S.**
* According to a study published by IMV Medical Information Division
**National Council on Radiation Protection and Measurements, report No. 168 (2010)
Q Inside SmartMarker
21*Source = ASTRO,American Society of Radiation Oncology
World’s first and only implantable wireless radiation dosimeter; FDA
cleared for use in prostate and breast cancer radiotherapy
Enables radiation oncologists to immediately measure the dose of radiation
penetrating a tumor or tumor area
Cleared for use in photon external beam and hypo-fractionated treatment protocols
Potential additional new indications for use include lung, colorectal and pancreatic
cancer
Only device that confirms radiation dose delivered to tumor
Can also be used as a fiducial marker for localization of the tumor
Device is reimbursable by both Medicare and private insurance
FDA cleared & CE mark; significant patent protection
Approximately 81,580 patients receive seed implants per year in the U.S. and
more than 425,000 patients are diagnosed with prostate and breast cancers
total each year in the U.S.*
Bio-Sensor Business Model
22
To be sold to radiation oncology centers in the U.S. and E.U.
Radiation oncologists, therapists, physicists, dosimetrists
Over 4,400 radiation oncologists in the U.S., with 4 states representing 33% of the
U.S. market
To be sold through direct sales, worldwide distribution partners, product
specific website, trade associations
Price for One Dose Reader Kit = $499; gross margin = 80%
Price for Q Inside SmartMarker Kit = $1,200; gross margin = 80%
Potential distribution partners:
Intellectual Property
23
VeriTeQ has a robust portfolio of more than 100 patents, patents pending and licenses in the U.S.
and abroad. VeriTeQ’s foundation patents are an Embedded Bio-Sensor System on the end of a RF
microchip (Patent 7,125,382 issued in 2006), and the use of implantable sensors for monitoring
tumors in oncology applications (Patent 6,402,689 issued in 2002). A partial list of the Company’s
key patents follows.
Patent No. Title
7,125,382 Embedded Bio-Sensor System
6,402,689 Methods, Systems and Associated Implantable Devices for Dynamic Monitoring of Physiological and Biological Properties of Tumors
7,378,056 Methods, Circuits, and Compositions of Matter for In Vivo Detection of Biomolecule Concentrations Using Fluorescent Tags
7,011,814 Systems, Methods And Devices For In Vivo Monitoring Of A Localized Response Via A Radiolabeled Analyte In A Subject
7,479,108 Implantable Sensor Housing, Sensor Unit And Methods For Forming And Using The Same
7,495,224 Disposable Single-Use External Dosimeters For Use In Radiation Therapies
7,966,054 Disposable Single-Use External Dosimeters For Detecting Radiation In Fluoroscopy And Other Medical Procedures/Therapies
7,491,942 Disposable Single-Use Internal Dosimeters For Detecting Radiation In Medical Procedures/Therapies
7,010,340 Methods, Systems, and Computer Program Products for Providing Dynamic Data of Positional Localization of Target Implants
7,510,699 In Vivo Fluorescence Sensors, Systems, And Related Methods Operating In Conjunction with Fluorescently Labeled Materials
7,557,353 Single-Use External Dosimeters for Use in Radiation Therapies and Related Methods, Systems and Computer Program Products
Leadership Team
24
Scott R. Silverman
Chairman & CEO
Mr. Silverman has been Chairman and CEO of VeriTeQ since its inception in Dec. 2011. He served as Chairman and CEO of
PositiveID Corp. (OTC:PSID) from 2008 to Aug. 2011, and Chairman and CEO of VeriChip Corp. (NASDAQ:CHIP) from
Dec. 2006 to Jul. 2008. He was Chairman of Digital Angel Corp. from 2003 to 2007. From 2003 to 2006, Mr. Silverman
served as Chairman and CEO of Applied Digital Solutions (NASDAQ:ADSX). Mr. Silverman is an attorney licensed to practice
in NJ and PA, and has more than 15 years of executive experience with technology companies. He is a graduate of the
University of Pennsylvania and Villanova School of Law.
Randolph K. Geissler
President
Mr. Geissler has been President of VeriTeQ since July 2012. He developed the implantable microchip, with more than 150
million microchips implanted in animals for identification and tracking. He previously served as CEO of Geissler Technologies
(2004 - 2008) when he sold the company's product development pipeline. Prior to that, he served as CEO of Digital Angel
Corp. (Amex: DOC) (2000 - 2003) and Destron Fearing (Nasdaq: DFCO) (1993 - 1999), a company he founded. He has taken
companies public and has broad experience in product development, electronic miniaturization, application of advanced
technologies in new markets, and extensive experience in establishing strategic intellectual property and patent portfolios.
Michael Krawitz
Chief Legal and
Financial Officer
Mr. Krawitz was most recently the CEO of Pear Energy, a renewable energy company that finances renewable energy and
energy efficiency projects. He previously served as CEO of Florida Sunshine Investments I, Inc., which manages more than $1
billion worth of properties throughout the United States. He is also a member of the Company's Board of Directors. Mr.
Krawitz earned a bachelor of arts degree from Cornell University and a Juris doctorate from Harvard Law School.
AllisonTomek
Sr.VP IR &
Corporate
Communications
Ms. Tomek has served as Sr. VP of VeriTeQ since its inception and has served as Sr. VP, IR and Corp Comm of PositiveID since
January 2007. From Jan. 2007 to Jun. 2008 she was also VP of IR at Applied Digital Solutions and Digital Angel. From 2003 to
2006, Ms. Tomek was Director of IR and Corp Comm at Andrx Corp. (NASDAQ:ADRX). Ms. Tomek is the former President
of the National Investor Relations Institute, South Florida chapter and a current member of its Board.
Capitalization
25
Shares
Held
Percent
Ownership
Officers and Directors 6,680,854 61%
Float 4,287,988 39%
TOTAL 10,968,842 100%
Near-Term Goals
26
First product launched; marketing of Motiva breast
implants with Q Inside SafetyTechnology in EU/UK
Enter into more partnership/supply agreements post
Final Rule
Enter into partnership for data analytics platform
development
Continued expansion of patent portfolio surrounding Q
Inside SafetyTechnology for medical devices
Additional future partnerships
Investment Highlights
27
Unique industry technology and market position for its Q Inside Safety
Technology unique device identification products
FDA cleared device that meets the UDI direct marking mandate for reusable medical
devices under the FDA Final Rule provides for “first to market” capability
IP provides strong competitive position for long term strategic advantage
Launch of Q Inside breast implants in Q1 2014
Commercial partnership with Establishment Labs/Motiva for ex-US markets
More than 500 women have received Motiva implants with Q Inside SafetyTechnology
Major US manufacturer currently in prototype stage
Preparing for immediate expansion into markets forVascular Ports and Orthopedic
Implants
Commercial partnership with MedComp in place
VeriTeQ Radiation Dosimetry products – ready to move into
commercialization
Radiation dosimeters used in the treatment of cancer
Unique patented technologies with multiple regulatory approvals provide
competitive advantage in respective markets
Q&A
Thank you!

More Related Content

What's hot

mock 510(k) for UCSC Extension Regulatory Submissions Devices and Diagnostics...
mock 510(k) for UCSC Extension Regulatory Submissions Devices and Diagnostics...mock 510(k) for UCSC Extension Regulatory Submissions Devices and Diagnostics...
mock 510(k) for UCSC Extension Regulatory Submissions Devices and Diagnostics...Joanne Pelaschier, RAC, CQA, CQE
 
PTC Successfully Submits Test Data to the FDA’s Global Unique Device Identifi...
PTC Successfully Submits Test Data to the FDA’s Global Unique Device Identifi...PTC Successfully Submits Test Data to the FDA’s Global Unique Device Identifi...
PTC Successfully Submits Test Data to the FDA’s Global Unique Device Identifi...PTC
 
Free webinar on Unique Device Identification
Free webinar on Unique Device IdentificationFree webinar on Unique Device Identification
Free webinar on Unique Device Identificationnykathlen
 
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...PharmaLedger
 
Anteo Diagnostics Research Report November 2015
Anteo Diagnostics Research Report November 2015Anteo Diagnostics Research Report November 2015
Anteo Diagnostics Research Report November 2015Matt Sanderson
 
Medical Device UDIs and Traceability Forum 2015
Medical Device UDIs and Traceability Forum 2015Medical Device UDIs and Traceability Forum 2015
Medical Device UDIs and Traceability Forum 2015Caralina Wonnacott
 
510K Table of Contents - Medical Device Description
510K Table of Contents - Medical Device Description510K Table of Contents - Medical Device Description
510K Table of Contents - Medical Device Descriptioncomplianceonline123
 
12 Steps for Medical Device UDI Submissions to the FDA GUDID
12 Steps for Medical Device UDI Submissions to the FDA GUDID12 Steps for Medical Device UDI Submissions to the FDA GUDID
12 Steps for Medical Device UDI Submissions to the FDA GUDIDJoe Hage
 
Unique Device Identification UDI Requirements and Timelines
Unique Device Identification UDI Requirements and Timelines Unique Device Identification UDI Requirements and Timelines
Unique Device Identification UDI Requirements and Timelines Joe Hage
 
Medical device regulations 510k
Medical device regulations 510kMedical device regulations 510k
Medical device regulations 510kSigma
 
8. medical device manufacturing breakout session
8. medical device manufacturing breakout session8. medical device manufacturing breakout session
8. medical device manufacturing breakout sessionGreaterRomeChamber
 
PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021
PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021
PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021PharmaLedger
 
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar PharmaLedger
 
Anteo Technologies Investor Presentation
Anteo Technologies Investor PresentationAnteo Technologies Investor Presentation
Anteo Technologies Investor PresentationMatt Sanderson
 
Abbreviated 510(k)
Abbreviated 510(k)Abbreviated 510(k)
Abbreviated 510(k)Tosha Dave
 
Anteo Technologies - New York presentation 2015
Anteo Technologies - New York presentation 2015Anteo Technologies - New York presentation 2015
Anteo Technologies - New York presentation 2015Matt Sanderson
 
Global unique device identification database (gudid) and udi
Global unique device identification database (gudid) and udiGlobal unique device identification database (gudid) and udi
Global unique device identification database (gudid) and udiJoe Hage
 
CDEX Inc Investors Presentation
CDEX Inc Investors PresentationCDEX Inc Investors Presentation
CDEX Inc Investors Presentationcdexinc
 

What's hot (20)

mock 510(k) for UCSC Extension Regulatory Submissions Devices and Diagnostics...
mock 510(k) for UCSC Extension Regulatory Submissions Devices and Diagnostics...mock 510(k) for UCSC Extension Regulatory Submissions Devices and Diagnostics...
mock 510(k) for UCSC Extension Regulatory Submissions Devices and Diagnostics...
 
PTC Successfully Submits Test Data to the FDA’s Global Unique Device Identifi...
PTC Successfully Submits Test Data to the FDA’s Global Unique Device Identifi...PTC Successfully Submits Test Data to the FDA’s Global Unique Device Identifi...
PTC Successfully Submits Test Data to the FDA’s Global Unique Device Identifi...
 
DCN Company Profile 2015
DCN Company Profile 2015DCN Company Profile 2015
DCN Company Profile 2015
 
Free webinar on Unique Device Identification
Free webinar on Unique Device IdentificationFree webinar on Unique Device Identification
Free webinar on Unique Device Identification
 
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
 
Anteo Diagnostics Research Report November 2015
Anteo Diagnostics Research Report November 2015Anteo Diagnostics Research Report November 2015
Anteo Diagnostics Research Report November 2015
 
Medical Device UDIs and Traceability Forum 2015
Medical Device UDIs and Traceability Forum 2015Medical Device UDIs and Traceability Forum 2015
Medical Device UDIs and Traceability Forum 2015
 
510K Table of Contents - Medical Device Description
510K Table of Contents - Medical Device Description510K Table of Contents - Medical Device Description
510K Table of Contents - Medical Device Description
 
12 Steps for Medical Device UDI Submissions to the FDA GUDID
12 Steps for Medical Device UDI Submissions to the FDA GUDID12 Steps for Medical Device UDI Submissions to the FDA GUDID
12 Steps for Medical Device UDI Submissions to the FDA GUDID
 
Unique Device Identification UDI Requirements and Timelines
Unique Device Identification UDI Requirements and Timelines Unique Device Identification UDI Requirements and Timelines
Unique Device Identification UDI Requirements and Timelines
 
Medical device regulations 510k
Medical device regulations 510kMedical device regulations 510k
Medical device regulations 510k
 
8. medical device manufacturing breakout session
8. medical device manufacturing breakout session8. medical device manufacturing breakout session
8. medical device manufacturing breakout session
 
PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021
PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021
PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021
 
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
 
Anteo Technologies Investor Presentation
Anteo Technologies Investor PresentationAnteo Technologies Investor Presentation
Anteo Technologies Investor Presentation
 
Abbreviated 510(k)
Abbreviated 510(k)Abbreviated 510(k)
Abbreviated 510(k)
 
Medical Device Regulations - 510(k) Process
Medical Device Regulations - 510(k) ProcessMedical Device Regulations - 510(k) Process
Medical Device Regulations - 510(k) Process
 
Anteo Technologies - New York presentation 2015
Anteo Technologies - New York presentation 2015Anteo Technologies - New York presentation 2015
Anteo Technologies - New York presentation 2015
 
Global unique device identification database (gudid) and udi
Global unique device identification database (gudid) and udiGlobal unique device identification database (gudid) and udi
Global unique device identification database (gudid) and udi
 
CDEX Inc Investors Presentation
CDEX Inc Investors PresentationCDEX Inc Investors Presentation
CDEX Inc Investors Presentation
 

Viewers also liked (20)

2003 looking back - 2004 looking ahead - jan-feb 2004
2003 looking back - 2004 looking ahead - jan-feb 20042003 looking back - 2004 looking ahead - jan-feb 2004
2003 looking back - 2004 looking ahead - jan-feb 2004
 
Onde se compra isso
Onde se compra issoOnde se compra isso
Onde se compra isso
 
DE Streaming
DE StreamingDE Streaming
DE Streaming
 
Protótipo do 666
 Protótipo do 666 Protótipo do 666
Protótipo do 666
 
Aker may 2014 investor presentation
Aker may 2014 investor presentationAker may 2014 investor presentation
Aker may 2014 investor presentation
 
DRNE INVESTOR PRESENTATION
DRNE INVESTOR PRESENTATIONDRNE INVESTOR PRESENTATION
DRNE INVESTOR PRESENTATION
 
Avth investor presentationredchip-13
Avth investor presentationredchip-13Avth investor presentationredchip-13
Avth investor presentationredchip-13
 
Efr 102013
Efr 102013Efr 102013
Efr 102013
 
Dss 6262013
Dss 6262013Dss 6262013
Dss 6262013
 
01 ogen
01 ogen01 ogen
01 ogen
 
Roil 102013
Roil 102013Roil 102013
Roil 102013
 
VeriTeQ Presentation at the Global Online CEO Conference July 2014
VeriTeQ Presentation at the Global Online CEO Conference July 2014VeriTeQ Presentation at the Global Online CEO Conference July 2014
VeriTeQ Presentation at the Global Online CEO Conference July 2014
 
Pfie 102013
Pfie 102013Pfie 102013
Pfie 102013
 
04 cgix
04 cgix04 cgix
04 cgix
 
Investor presentation usell.com
Investor presentation usell.comInvestor presentation usell.com
Investor presentation usell.com
 
Cgix vc oct2013
Cgix vc oct2013Cgix vc oct2013
Cgix vc oct2013
 
EXEO Presentation April 2014
EXEO Presentation April 2014EXEO Presentation April 2014
EXEO Presentation April 2014
 
08 btcs
08 btcs08 btcs
08 btcs
 
BIOC Presentation April 2014
BIOC Presentation April 2014BIOC Presentation April 2014
BIOC Presentation April 2014
 
Asur 6262013
Asur 6262013Asur 6262013
Asur 6262013
 

Similar to VTEQ Presentation july 2014

Aditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationAditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationRedChip Companies, Inc.
 
Digital Therapeutics Regulatory Process, Update and Trends
Digital Therapeutics Regulatory Process, Update and TrendsDigital Therapeutics Regulatory Process, Update and Trends
Digital Therapeutics Regulatory Process, Update and TrendsInsights10
 
Stc384 team phoenix scenario analysis exec summary approval from ccm
Stc384 team phoenix scenario analysis exec summary approval from ccmStc384 team phoenix scenario analysis exec summary approval from ccm
Stc384 team phoenix scenario analysis exec summary approval from ccmClaudia Chittim
 
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationAdvanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationRedChip Companies, Inc.
 
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationAdvanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationRedChip Companies, Inc.
 
Visionstate Corporate Presentation: August 2022
Visionstate Corporate Presentation: August 2022Visionstate Corporate Presentation: August 2022
Visionstate Corporate Presentation: August 2022CHF Investor Relations
 
Market access medical devices-white paper
Market access medical devices-white paperMarket access medical devices-white paper
Market access medical devices-white paperDr. Kavita Lamror
 
Market access medical devices white paper
Market access medical devices white paperMarket access medical devices white paper
Market access medical devices white paperDr. Kavita Lamror
 
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021Levi Shapiro
 
Fundability Criteria Worksheet_MediCoventures_v3.1
Fundability Criteria Worksheet_MediCoventures_v3.1Fundability Criteria Worksheet_MediCoventures_v3.1
Fundability Criteria Worksheet_MediCoventures_v3.1Aaron Call
 
Public Device & Biopharma Ophthalmology Company Showcase - pSivida
Public Device & Biopharma Ophthalmology Company Showcase - pSividaPublic Device & Biopharma Ophthalmology Company Showcase - pSivida
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
 
Johnson & Johnson Pharmaceutical Business Review
Johnson & Johnson Pharmaceutical Business ReviewJohnson & Johnson Pharmaceutical Business Review
Johnson & Johnson Pharmaceutical Business ReviewDeepa K
 
Ventripoint Diagnostics Ltd investor presentation
Ventripoint Diagnostics Ltd investor presentationVentripoint Diagnostics Ltd investor presentation
Ventripoint Diagnostics Ltd investor presentationChadLevesque1
 
Genetic Technologies Investor Presentation Jan 2022
Genetic Technologies Investor Presentation Jan 2022Genetic Technologies Investor Presentation Jan 2022
Genetic Technologies Investor Presentation Jan 2022RedChip Companies, Inc.
 

Similar to VTEQ Presentation july 2014 (20)

Aditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationAditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) Presentation
 
Freyr UDI Services
Freyr UDI ServicesFreyr UDI Services
Freyr UDI Services
 
Digital Therapeutics Regulatory Process, Update and Trends
Digital Therapeutics Regulatory Process, Update and TrendsDigital Therapeutics Regulatory Process, Update and Trends
Digital Therapeutics Regulatory Process, Update and Trends
 
Stc384 team phoenix scenario analysis exec summary approval from ccm
Stc384 team phoenix scenario analysis exec summary approval from ccmStc384 team phoenix scenario analysis exec summary approval from ccm
Stc384 team phoenix scenario analysis exec summary approval from ccm
 
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationAdvanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. Presentation
 
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationAdvanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. Presentation
 
ieCrowd Pesentation
ieCrowd PesentationieCrowd Pesentation
ieCrowd Pesentation
 
Visionstate Corporate Presentation: August 2022
Visionstate Corporate Presentation: August 2022Visionstate Corporate Presentation: August 2022
Visionstate Corporate Presentation: August 2022
 
Market access medical devices-white paper
Market access medical devices-white paperMarket access medical devices-white paper
Market access medical devices-white paper
 
Market access medical devices white paper
Market access medical devices white paperMarket access medical devices white paper
Market access medical devices white paper
 
160428_WP_Medical_UDI_EN.PDF
160428_WP_Medical_UDI_EN.PDF160428_WP_Medical_UDI_EN.PDF
160428_WP_Medical_UDI_EN.PDF
 
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
Taking The Pulse of Medtech innovation_Pitchbook, Dec, 2021
 
eDevice Award Write Up
eDevice Award Write UpeDevice Award Write Up
eDevice Award Write Up
 
Sharps Technology Investor Presentation
Sharps Technology Investor PresentationSharps Technology Investor Presentation
Sharps Technology Investor Presentation
 
Fundability Criteria Worksheet_MediCoventures_v3.1
Fundability Criteria Worksheet_MediCoventures_v3.1Fundability Criteria Worksheet_MediCoventures_v3.1
Fundability Criteria Worksheet_MediCoventures_v3.1
 
Public Device & Biopharma Ophthalmology Company Showcase - pSivida
Public Device & Biopharma Ophthalmology Company Showcase - pSividaPublic Device & Biopharma Ophthalmology Company Showcase - pSivida
Public Device & Biopharma Ophthalmology Company Showcase - pSivida
 
Johnson & Johnson Pharmaceutical Business Review
Johnson & Johnson Pharmaceutical Business ReviewJohnson & Johnson Pharmaceutical Business Review
Johnson & Johnson Pharmaceutical Business Review
 
Ventripoint Diagnostics Ltd investor presentation
Ventripoint Diagnostics Ltd investor presentationVentripoint Diagnostics Ltd investor presentation
Ventripoint Diagnostics Ltd investor presentation
 
Advamed MDR IVDR update
Advamed MDR IVDR updateAdvamed MDR IVDR update
Advamed MDR IVDR update
 
Genetic Technologies Investor Presentation Jan 2022
Genetic Technologies Investor Presentation Jan 2022Genetic Technologies Investor Presentation Jan 2022
Genetic Technologies Investor Presentation Jan 2022
 

More from RedChip Companies, Inc.

Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference  Small Stocks...Big North Graphite : Presenting at Global Online CEO Conference  Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
 
Btcs corporate presentation july 2014 final
Btcs corporate presentation  july 2014 finalBtcs corporate presentation  july 2014 final
Btcs corporate presentation july 2014 finalRedChip Companies, Inc.
 
Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21RedChip Companies, Inc.
 
Intercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO ConferenceIntercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO ConferenceRedChip Companies, Inc.
 
Lightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO ConferenceLightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
Roil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO ConferenceRoil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
Neo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO ConferenceNeo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
American water works red_chip's global online ceo conference
American water works red_chip's global online ceo conferenceAmerican water works red_chip's global online ceo conference
American water works red_chip's global online ceo conferenceRedChip Companies, Inc.
 
Exeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO ConferenceExeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
Direct Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO ConferenceDirect Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
Lattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO ConferenceLattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 
QFOR: RedChip's Global Online CEO Conference
QFOR: RedChip's Global Online CEO ConferenceQFOR: RedChip's Global Online CEO Conference
QFOR: RedChip's Global Online CEO ConferenceRedChip Companies, Inc.
 

More from RedChip Companies, Inc. (20)

Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference  Small Stocks...Big North Graphite : Presenting at Global Online CEO Conference  Small Stocks...
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...
 
The Coin Tree media kit deck
The Coin Tree   media kit deckThe Coin Tree   media kit deck
The Coin Tree media kit deck
 
StarStream Entertainment
StarStream EntertainmentStarStream Entertainment
StarStream Entertainment
 
StarStream Entertainment
StarStream EntertainmentStarStream Entertainment
StarStream Entertainment
 
StarStream Entertainment
StarStream EntertainmentStarStream Entertainment
StarStream Entertainment
 
Ir presentation 062314
Ir presentation 062314Ir presentation 062314
Ir presentation 062314
 
Btcs corporate presentation july 2014 final
Btcs corporate presentation  july 2014 finalBtcs corporate presentation  july 2014 final
Btcs corporate presentation july 2014 final
 
Red chip preso 7 11-14
Red chip preso 7 11-14Red chip preso 7 11-14
Red chip preso 7 11-14
 
Gbi investor deck_12.04_revised
Gbi investor deck_12.04_revisedGbi investor deck_12.04_revised
Gbi investor deck_12.04_revised
 
Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21Station digital corporate_road_show_lr_medium v21
Station digital corporate_road_show_lr_medium v21
 
Intercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO ConferenceIntercloud Systems: Global Online CEO Conference
Intercloud Systems: Global Online CEO Conference
 
Atnm julyconference
Atnm julyconferenceAtnm julyconference
Atnm julyconference
 
Lightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO ConferenceLightbridge: RedChip's Global Online CEO Conference
Lightbridge: RedChip's Global Online CEO Conference
 
Roil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO ConferenceRoil: RedChip's Global Online CEO Conference
Roil: RedChip's Global Online CEO Conference
 
Neo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO ConferenceNeo stem RedChip's Global Online CEO Conference
Neo stem RedChip's Global Online CEO Conference
 
American water works red_chip's global online ceo conference
American water works red_chip's global online ceo conferenceAmerican water works red_chip's global online ceo conference
American water works red_chip's global online ceo conference
 
Exeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO ConferenceExeo: RedChip's Global Online CEO Conference
Exeo: RedChip's Global Online CEO Conference
 
Direct Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO ConferenceDirect Insite: RedChip's Global Online CEO Conference
Direct Insite: RedChip's Global Online CEO Conference
 
Lattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO ConferenceLattice: RedChip's Global Online CEO Conference
Lattice: RedChip's Global Online CEO Conference
 
QFOR: RedChip's Global Online CEO Conference
QFOR: RedChip's Global Online CEO ConferenceQFOR: RedChip's Global Online CEO Conference
QFOR: RedChip's Global Online CEO Conference
 

Recently uploaded

(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptxMrStavanUdayKadam
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUKanhu Charan
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxVeereshDemashetti
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxsiddharthroy26587
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONojaswinihemane
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...Genesis Institute of Pharmacy, Radhanagari.
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 

Recently uploaded (20)

(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptx
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptx
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptx
 
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 

VTEQ Presentation july 2014

  • 2. Safe Harbor Statement 2 Statements made in this presentation regarding VeriTeQ Corporation (“VeriTeQ” or “Company”) and VeriTeQ that are not historical facts are forward-looking statements based on our current expectations, assumptions, estimates and projections about VeriTeQ and our industry. These forward-looking statements are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. These forward-looking statements include, without limitation, statements about our proposed name change and reverse stock split, our commercialization activities, market opportunities, our strategy, our competition, FDA regulation, partnership opportunities, market penetration, and all other forward-looking statements. You should not place undue reliance on any of the forward-looking statements made in this presentation. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including risks and uncertainties related to the timing or successful completion of our product commercialization activities, VeriTeQ’s ability to raise capital, and other various risks and uncertainties. Additional information about these and other factors that could affect VeriTeQ’s business is set forth in its various filings with the Securities and Exchange Commission, including those set forth in its Form 10-K filed on April 15, 2014, and Forms 10-Q filed on July 16, 2013 and November 14, 2013, and May 14, 2014 under the caption "Risk Factors." The Company undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. This presentation does not constitute a prospectus or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, or any offer to underwrite or otherwise acquire any shares in the Company or any other securities, nor shall they or any part of them nor the fact of their distribution or communication form the basis of, or be relied on in connection with, any contract, commitment or investment decision in relation thereto, nor does it constitute a recommendation regarding the securities of the Company.
  • 3. Company Background 3 VeriTeQ originated as a private company founded in 2011 to acquire and develop core implantable RFID intellectual property for healthcare Acquired/licensed/developed 100+ patents (issued or pending) Multiple regulatory clearances: FDA and CE Mark Completed share exchange agreement with DigitalAngel Corporation on July 8, 2013; company changed its name toVeriTeQ VeriTeQ shareholders own ~88% of resulting company Closed $1.5m bridge financing on Nov. 13 Ticker changed to “VTEQ” on Nov. 19
  • 4. Unique Value Proposition 4 In July 2012, the Healthcare Safety and Innovation Act was signed into law and in Sept. 2013, the FDA issued a Final Rule requiring all medical devices in the U.S. that are re- usable and re-processed to carry a unique device identifier, or UDI, with direct part marking VeriTeQ’s FDA cleared UDI, called Q Inside SafetyTechnology, can serve as a direct part marking to help device manufacturers comply with the Final Rule, and can also identify a permanent implantable medical device, in vivo, on demand Q Inside SafetyTechnology goes beyond device identification and provides clinical and healthcare benefits via customizable software and data analytics VeriTeQ also offers FDA cleared radiation dose measurement technologies to protect patients undergoing cancer treatment VeriTeQ’s implantable and wearable dosimetry products provide radiation levels from the patient to help prevent overdose and under-dose
  • 5. Company Overview 5 VeriTeQ provides proprietary, innovative healthcare solutions for Unique Device Identification and Bio-Sensing/Radiation Dosimetry applications CoreTechnology: implantable radio frequency (RF) microchip technology Cleared by the FDA as the Predicate Class II medical device in the industry UDI products enable access to UDI information, in-situ, on demand, at the point of use A leading industry position to enable compliance with FDA Final Rule Q Inside SafetyTechnology also enables data analytics for evidence-based medicine Bio-sensing technologies for radiation dosimetry provide real-time measurements of received radiation dose from the patient, not the machine External and internal product applications Helps prevent radiation overdosing and under-dosing
  • 6. Lead Business Areas 6 Medical Device UDI/Q Inside SafetyTechnology Breast Implants and Breast Implant Sizers Vascular Ports Other Reusable and Implantable Medical Devices Bio- Sensing/Radiation Dosimeter Technologies External Radiation Dosimeter Implantable Radiation Dosimeter
  • 7. TheVeriTeQ UDI System Medical Devices with Inside SafetyTechnology 7
  • 8. FDA Final Rule 8 The Final Rule requires devices intended to be used more than once and intended to undergo any form of reprocessing before each use, i.e. re-useable/reprocessed medical devices to have a direct part marking (vs. basic labeling on device packaging) Requires the direct part marking to be provided through either or both of the following: Easily readable plain text; Automatic Identification and Data Capture (AIDC), or an alternative technology, that will provide the UDI of the device on demand Benefits of a UDI System Allows more accurate reporting and analysis of adverse events to quickly identify problem devices Reduces medical errors by quickly and accurately identifying a device and its characteristics Provides a standardized identifier that allows manufacturers, distributors and healthcare facilities to more effectively manage medical device recalls Provides a consistent way to enter information about devices in electronic health records and clinical information systems Provides a foundation for a global, secure distribution chain, helping to address counterfeiting and diversion and prepare for medical emergencies
  • 9.  Implantable RFID Microchips  Patented and FDA cleared  Provides the primary key information  Pocket Readers  Patented and FDA Cleared  Pocket Reader  Pocket Reader EX VeriTeQ’s UDI System: Inside  Database  Customization for device manufacturer  Informatics  Integration with FDA database 9
  • 10. UDI Business Model 10 VeriTeQ acts primarily as a supplier of its proprietary microchips and readers to medical device manufacturers Manufacturers incorporateVeriTeQ’s products into their manufacturing processes/distribution strategy (to hospitals, physicians, etc.) Price per chip = $12-15; gross margin per chip = 65 - 75% margins Price per reader = $300-500; gross margin per reader = 40 – 60% margins VeriTeQ also provides development services to medical device manufacturers Primary development areas include design and manufacturing process to include chip in their medical device, i.e. new encasement technologies such as special polymers and heat resistant microchips Avg. price for development per manufacturer = $250,000; gross margin = 50% Data services include database connectivity to manufactured microchips, application software to collect microchip/medical device model implanted, FDA data base registry and informatics analytics. Priced on per project development ranging from $25,000 to several hundred thousand dollars
  • 12. Breast Implants 12 VeriTeQ’s Q Inside SafetyTechnology can be embedded within breast implants and sizers to automatically identify the medical device in situ or after re-sterilization. Ex-US:Agreement with Establishment Labs/Motiva Leading global breast, body and facial aesthetic company that manufactures advanced silicone-filled breast implants, marketed under the Motiva Implant Matrix brand name Manufacturing completed and CE Mark certifications achieved Launched Q1-2014 (EU and UK); Over 500 women implanted US: Market leading breast implant manufacturer is testing feasibility to integrate the Q Inside in its silicone implants and sizers Discussions ongoing with the two leading global breast implant manufacturers regarding need to identify their sizers to comply with FDA Final Rule Company estimates sizer market at 600,000 devices annually
  • 13. Vascular Ports 13 Partnership with Medcomp (a leading manufacturer of vascular ports) to utilize Q Inside for Medcomp’s FDA-cleared vascular ports $3 million initial contractual PO commitment from Medcomp Enables accurate device identification and medication dosage Hospital studies expected to begin at: Northwestern Memorial in Chicago NewYork-Presbyterian – University Hospital of Columbia and Cornell in NY Cleveland Clinic in Cleveland, OH or MDAnderson Cancer Center in Houston,TX Medcomp /VeriTeQ targeting to set clinical UDI standard to incentivize other port manufacturers to use Q Inside – e.g. C.R. Bard, Smiths Medical, etc.
  • 14. Artificial Joints and Sizers 14 Identification of implantable and reusable medical devices such as sizers used in joint replacements (subject to Final Rule) Artificial hips in the U.S.: Number of procedures: 230,000 Total annual expenditure: $10.5 billion Average cost per procedure: $45,000 Major manufacturers: Zimmer (24%), Stryker, DePuy/J&J, Biomet,Wright Medical Artificial knees in the U.S. Number of procedures: 543,000 Total annual expenditure: $12 billion Average cost per procedure: $22,000 Major manufacturers: Zimmer (24%), Depuy/J&J, Stryker, Biomet, Smith & Nephew Active initial meetings/dialog with lead target device manufacturers Clinical benefits: Q Inside SafetyTechnology allows for immediate data retrieval; can help quickly resolve adverse event reporting and recalls As published on July 18,2011 in 24/7Wall St.’s Eleven Most Implanted Medical Devices In America
  • 15. VeriTeQ Bio-Sensors In Situ Measurement of Radiation Dosages 15
  • 16. Sensing Technologies 16 VeriTeQ owns Patent 7,125,382 for an “Embedded Bio-Sensor System,” a biological sensor on the end of a radio frequency chip Temperature (current) Radiation levels (current) Blood oxygen (future) Pulse (future) Medication levels (future) i.e. post surgery Glucose (licensed to a third party) Others
  • 17. VeriTeQ Dosimetry OneDose ExternalTechnology Q Inside SmartMarker ImplantableTechnology Radiation DoseVerification 17
  • 18. Maximize Tumor Control (High Dose) Minimize Healthy Tissue Toxicity (Low Dose) The greatest challenge for radiation therapy or any cancer therapy is to attain the highest probability of cure with the least morbidity.1 1) Bucci MK, Bevan A and Roach M. Ca Cancer J Clin 2005;55:117-134 Objective of the Radiation Oncologist 18
  • 19. Patient Safety & Radiation Overdose 19 2013: #3 Unnecessary exposures and radiation burns from diagnostic radiology procedures 2012: #2 Exposure hazards from radiation therapy and CT 2011: #1 Radiation overdose and other errors during radiation therapy 2009-10: #4 CT radiation dose 2008: #8 CT radiation dose 2007: #5 Radiation therapy errors According to the ECRI Institute, radiation or CT overdose make the list of theTop 10Technology Hazards each year going back at least five years
  • 20. VeriTeQ OneDose ® 20 OneDose® is an FDA-cleared single-use, external dosimetry system used in the radiation oncology suite to verify radiation dose quickly and conveniently at the skin level Significant IP protection CE Mark to market products in the E.U. OneDose is the only wireless, pre-calibrated, disposable, surface sensor on the market that provides an instant readout of the dose delivered Reimbursement rate per patient (4-6 dosimeters used during treatment) ranges between $260 and $380 In 2010, 1.1 million patients received radiation therapy in the U.S.* with new indications for use in CT and fluoroscopy markets Researchers at the National Cancer Institute estimate that 29,000 future cancer cases could be attributed to the 72 million CT scans performed in the country in 2007 Over 5 million fluoroscopic procedures performed annually in the U.S.** * According to a study published by IMV Medical Information Division **National Council on Radiation Protection and Measurements, report No. 168 (2010)
  • 21. Q Inside SmartMarker 21*Source = ASTRO,American Society of Radiation Oncology World’s first and only implantable wireless radiation dosimeter; FDA cleared for use in prostate and breast cancer radiotherapy Enables radiation oncologists to immediately measure the dose of radiation penetrating a tumor or tumor area Cleared for use in photon external beam and hypo-fractionated treatment protocols Potential additional new indications for use include lung, colorectal and pancreatic cancer Only device that confirms radiation dose delivered to tumor Can also be used as a fiducial marker for localization of the tumor Device is reimbursable by both Medicare and private insurance FDA cleared & CE mark; significant patent protection Approximately 81,580 patients receive seed implants per year in the U.S. and more than 425,000 patients are diagnosed with prostate and breast cancers total each year in the U.S.*
  • 22. Bio-Sensor Business Model 22 To be sold to radiation oncology centers in the U.S. and E.U. Radiation oncologists, therapists, physicists, dosimetrists Over 4,400 radiation oncologists in the U.S., with 4 states representing 33% of the U.S. market To be sold through direct sales, worldwide distribution partners, product specific website, trade associations Price for One Dose Reader Kit = $499; gross margin = 80% Price for Q Inside SmartMarker Kit = $1,200; gross margin = 80% Potential distribution partners:
  • 23. Intellectual Property 23 VeriTeQ has a robust portfolio of more than 100 patents, patents pending and licenses in the U.S. and abroad. VeriTeQ’s foundation patents are an Embedded Bio-Sensor System on the end of a RF microchip (Patent 7,125,382 issued in 2006), and the use of implantable sensors for monitoring tumors in oncology applications (Patent 6,402,689 issued in 2002). A partial list of the Company’s key patents follows. Patent No. Title 7,125,382 Embedded Bio-Sensor System 6,402,689 Methods, Systems and Associated Implantable Devices for Dynamic Monitoring of Physiological and Biological Properties of Tumors 7,378,056 Methods, Circuits, and Compositions of Matter for In Vivo Detection of Biomolecule Concentrations Using Fluorescent Tags 7,011,814 Systems, Methods And Devices For In Vivo Monitoring Of A Localized Response Via A Radiolabeled Analyte In A Subject 7,479,108 Implantable Sensor Housing, Sensor Unit And Methods For Forming And Using The Same 7,495,224 Disposable Single-Use External Dosimeters For Use In Radiation Therapies 7,966,054 Disposable Single-Use External Dosimeters For Detecting Radiation In Fluoroscopy And Other Medical Procedures/Therapies 7,491,942 Disposable Single-Use Internal Dosimeters For Detecting Radiation In Medical Procedures/Therapies 7,010,340 Methods, Systems, and Computer Program Products for Providing Dynamic Data of Positional Localization of Target Implants 7,510,699 In Vivo Fluorescence Sensors, Systems, And Related Methods Operating In Conjunction with Fluorescently Labeled Materials 7,557,353 Single-Use External Dosimeters for Use in Radiation Therapies and Related Methods, Systems and Computer Program Products
  • 24. Leadership Team 24 Scott R. Silverman Chairman & CEO Mr. Silverman has been Chairman and CEO of VeriTeQ since its inception in Dec. 2011. He served as Chairman and CEO of PositiveID Corp. (OTC:PSID) from 2008 to Aug. 2011, and Chairman and CEO of VeriChip Corp. (NASDAQ:CHIP) from Dec. 2006 to Jul. 2008. He was Chairman of Digital Angel Corp. from 2003 to 2007. From 2003 to 2006, Mr. Silverman served as Chairman and CEO of Applied Digital Solutions (NASDAQ:ADSX). Mr. Silverman is an attorney licensed to practice in NJ and PA, and has more than 15 years of executive experience with technology companies. He is a graduate of the University of Pennsylvania and Villanova School of Law. Randolph K. Geissler President Mr. Geissler has been President of VeriTeQ since July 2012. He developed the implantable microchip, with more than 150 million microchips implanted in animals for identification and tracking. He previously served as CEO of Geissler Technologies (2004 - 2008) when he sold the company's product development pipeline. Prior to that, he served as CEO of Digital Angel Corp. (Amex: DOC) (2000 - 2003) and Destron Fearing (Nasdaq: DFCO) (1993 - 1999), a company he founded. He has taken companies public and has broad experience in product development, electronic miniaturization, application of advanced technologies in new markets, and extensive experience in establishing strategic intellectual property and patent portfolios. Michael Krawitz Chief Legal and Financial Officer Mr. Krawitz was most recently the CEO of Pear Energy, a renewable energy company that finances renewable energy and energy efficiency projects. He previously served as CEO of Florida Sunshine Investments I, Inc., which manages more than $1 billion worth of properties throughout the United States. He is also a member of the Company's Board of Directors. Mr. Krawitz earned a bachelor of arts degree from Cornell University and a Juris doctorate from Harvard Law School. AllisonTomek Sr.VP IR & Corporate Communications Ms. Tomek has served as Sr. VP of VeriTeQ since its inception and has served as Sr. VP, IR and Corp Comm of PositiveID since January 2007. From Jan. 2007 to Jun. 2008 she was also VP of IR at Applied Digital Solutions and Digital Angel. From 2003 to 2006, Ms. Tomek was Director of IR and Corp Comm at Andrx Corp. (NASDAQ:ADRX). Ms. Tomek is the former President of the National Investor Relations Institute, South Florida chapter and a current member of its Board.
  • 25. Capitalization 25 Shares Held Percent Ownership Officers and Directors 6,680,854 61% Float 4,287,988 39% TOTAL 10,968,842 100%
  • 26. Near-Term Goals 26 First product launched; marketing of Motiva breast implants with Q Inside SafetyTechnology in EU/UK Enter into more partnership/supply agreements post Final Rule Enter into partnership for data analytics platform development Continued expansion of patent portfolio surrounding Q Inside SafetyTechnology for medical devices Additional future partnerships
  • 27. Investment Highlights 27 Unique industry technology and market position for its Q Inside Safety Technology unique device identification products FDA cleared device that meets the UDI direct marking mandate for reusable medical devices under the FDA Final Rule provides for “first to market” capability IP provides strong competitive position for long term strategic advantage Launch of Q Inside breast implants in Q1 2014 Commercial partnership with Establishment Labs/Motiva for ex-US markets More than 500 women have received Motiva implants with Q Inside SafetyTechnology Major US manufacturer currently in prototype stage Preparing for immediate expansion into markets forVascular Ports and Orthopedic Implants Commercial partnership with MedComp in place VeriTeQ Radiation Dosimetry products – ready to move into commercialization Radiation dosimeters used in the treatment of cancer Unique patented technologies with multiple regulatory approvals provide competitive advantage in respective markets